Mancini JG, et al. Am J Cardiol.

Slides:

Advertisements

Similar presentations

The EMERALD Trial Diabetic Substudy. EMERALD Diabetic Analysis To compare myocardial perfusion and infarct sizes in diabetic and non-diabetic patients.

Advertisements

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

on behalf of the TOTAL Investigators

TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.

‘SMASH IT!’ Mark Mason Interventional Cardiologist Harefield Hospital

University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.

The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,

ATTEMPT study: pooled-Analysis of Trials on ThrombEctomy in acute Myocardial infarction based on individual PatienT data CLINICAL TRIAL UPDATE III ESC.

Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.

Improving outcome of STEMI PCI: Preliminary Results of Crystal AMI trial Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators.

ReoPro ® in NSTEMI and STEMI Trials Harald Vangerow, MD Clinical Research Physician Eli Lilly UK.

on behalf of the TOTAL Investigators

UNIVERSITÄT LEIPZIG H E R Z Z E N T R U M Infarct transmurality and infarct size assessed by delayed enhancement magnetic resonance imaging: Association.

Primary angioplasty Thrombectomy and choice of stents Adam de Belder Sussex Cardiac Centre Brighton UK ACI 2011.

For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2013 Medtronic, Inc. All rights reserved. UC ML.

The MASTER Trial A Prospective, Randomized, Multicenter Evaluation of a PET Micronet Mesh Covered Stent (MGuard) in STEMI Sigmund Silber, MD, PhD FESC,

↓ 30 d mortality ↓ Distal embolization ↑ Myocardial Blush 3 ↑TIMI 3 Post De Luca et al. EHJ 2008;29:

2-Year Outcomes following Surgical Treatment of Moderate Ischemic Mitral Regurgitation: The Cardiothoracic Surgical Trials Network Robert E. Michler,

Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.

Rationale for TOTAL trial: randomized trial of routine aspiration ThrOmbecTomy with PCI vs. PCI ALone in patients with STEMI undergoing primary PCI Sanjit.

Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL) Stefan James Professor of Cardiology Uppsala Clinical.

IABP-SHOCK II Score Stratifies Patient Risk in CS after AMI

LEADER trial: Primary Outcome

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

DES Should be Used as the Default Stent in ACS!

Is There a Role for Aspiration in STEMI?

EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.

Effect of Obesity on In-Hospital Mortality in Patients with Cardiogenic Shock Complicating AMI Obesity is paradoxically associated with favorable mortality.

No Reflow Reflow P value Arrhythmia 40% 18% Lecture Notes

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

Figure 4 Pharmacodynamic comparison of crushed versus integral

Angiography-guided PCI

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Median total new lesion volume

Relative Risk of Events by CHA2DS2-VASc Score

Fewer PCIs After Public Reporting Changes in NY

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

Modified Rankin score 0-2

Relative risk of major events with atenolol vs placebo

Outcome Relative risk with beta blockers 95% CI Stroke –1.30

Figure 1 PCI strategies in patients with STEMI and multivessel disease

Nat. Rev. Cardiol. doi: /nrcardio

A Systematic Review and Meta-analysis of Randomized Trials of Manual Thrombectomy in ST elevation myocardial infarction Investigators: Ashraf Alazzoni,

Published in the European Heart Journal

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

EXPLORE Trial design: Patients with STEMI treated with primary PCI and with evidence of noninfarct artery chronic total occlusion (CTO) were randomized.

Figure 4 Observational studies on multiple treatment strategies

BRAVO-3 Trial design: Patients undergoing transfemoral TAVR were randomized in a 1:1 fashion to bivalirudin or UFH. They were followed for 30 days. Results.

Ezetimibe/simvastatin

Nat. Rev. Cardiol. doi: /nrcardio

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Nat. Rev. Cardiol. doi: /nrcardio

Ischemic Postconditioning

Patient characteristics: American vs Canadian transplant patients

Maintenance of Long-Term Clinical Benefit with

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

MOMENTUM 3 Trial design: Patients with advanced heart failure were randomized to a centrifugal-flow pump (n = 152) vs. an axial-flow pump (n = 142). Results.

IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.

Evolution of Myocardial Blush after MI

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

MRRs and EMRRs for women with ACS

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Presentation transcript:

Mancini JG, et al. Am J Cardiol. Meta-analysis of the Long-Term Effect of Routine Aspiration Thrombectomy in Primary PCI Patients 18 studies of > 20,000 STEMI patients with follow-up of at least 6 months. Outcomes at Longest Follow-Up: Routine Thrombectomy vs Primary PCI Alone RR 95% CI All-Cause Mortality 0.92 0.81-1.04 Stroke 1.59 1.07-2.35 ST-Segment Resolution 1.22 1.07-1.40 Myocardial Blush Grade 3 1.30 1.01-1.67 Conclusion: Data confirm there is no clinical benefit with routine aspiration thrombectomy in primary PCI and points to a possible increase in stroke risk. Mancini JG, et al. Am J Cardiol. 2016;Epub ahead of print.